We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.7B
AUM Growth
-$152M
Cap. Flow
+$293M
Cap. Flow %
3.03%
Top 10 Hldgs %
29.73%
Holding
234
New
14
Increased
60
Reduced
64
Closed
43

Top Buys

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$74.9M
2
ABT icon
Abbott
ABT
+$45.9M
3
MOH icon
Molina Healthcare
MOH
+$43.5M
4
DHR icon
Danaher
DHR
+$42M
5
MDT icon
Medtronic
MDT
+$38M

Top Sells

Rank Stock Value
1
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$63.1M
2
BAX icon
Baxter International
BAX
+$38.1M
3
CNC icon
Centene
CNC
+$36.2M
4
HOLX
Hologic
HOLX
+$21.4M
5
DXCM icon
DexCom
DXCM
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Technology 0.8%
3 Industrials 0.75%
4 Communication Services 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
76
DELISTED
Masimo
MASI
$38.5M 0.4%
131,376
+3,663
+3% +$1.04M
HCM icon
77
HUTCHMED
HCM
$1.86B
$37.8M 0.39%
1,076,870
+70,723
+7% +$2.3M
COO icon
78
Cooper Companies
COO
$14B
$34.9M 0.36%
333,276
+36,212
+12% +$3.69M
ATRC icon
79
AtriCure
ATRC
$1.77B
$34.7M 0.36%
498,556
+80,540
+19% +$5.85M
TXG icon
80
10x Genomics
TXG
$5.55B
$34.7M 0.36%
232,672
– –
ZBH icon
81
Zimmer Biomet
ZBH
$17.6B
$34.5M 0.36%
279,326
-9,158
-3% -$1.2M
TDOC icon
82
Teladoc Health
TDOC
$1.7B
$33.4M 0.34%
363,216
+147,310
+68% +$17.6M
TFX icon
83
Teleflex
TFX
$5.96B
$32.1M 0.33%
97,771
-47
-0% -$16K
PACB icon
84
Pacific Biosciences
PACB
$447M
$31.8M 0.33%
1,553,023
-90,136
-5% -$2.18M
APLS
85
DELISTED
Apellis Pharmaceuticals
APLS
$30.8M 0.32%
650,591
+602,591
+1,255% +$23.7M
LEGN icon
86
Legend Biotech
LEGN
$4.31B
$30.7M 0.32%
657,656
+371,100
+130% +$18.8M
BIO icon
87
Bio-Rad Laboratories Class A
BIO
$8.15B
$30M 0.31%
39,683
-6,332
-14% -$4.74M
GH icon
88
Guardant Health
GH
$20.7B
$29.4M 0.3%
293,612
-46,282
-14% -$4.79M
BNTX icon
89
BioNTech
BNTX
$23.1B
$29.3M 0.3%
113,466
+100,766
+793% +$27.6M
ILMN icon
90
Illumina
ILMN
$28.2B
$28.6M 0.29%
77,234
+5,140
+7% +$1.95M
HCAT icon
91
Health Catalyst
HCAT
$166M
$27.4M 0.28%
692,666
-34,567
-5% -$1.58M
GBIO
92
DELISTED
Generation Bio
GBIO
$27.4M 0.28%
387,218
+140,000
+57% +$24.4M
MRSN
93
DELISTED
Mersana Therapeutics
MRSN
$25.9M 0.27%
166,560
-3,880
-2% -$755K
OM icon
94
Outset Medical
OM
$77.9M
$25.8M 0.27%
37,374
+6,903
+23% +$5.1M
CRL icon
95
Charles River Laboratories
CRL
$10.8B
$24.8M 0.26%
65,911
+2,582
+4% +$1M
PHR icon
96
Phreesia
PHR
$662M
$24.7M 0.25%
592,327
-30,215
-5% -$1.79M
AXSM icon
97
Axsome Therapeutics
AXSM
$11.8B
$24.6M 0.25%
651,937
-101,008
-13% -$3.72M
CVS icon
98
CVS Health
CVS
$137B
$23.6M 0.24%
228,798
+70,250
+44% +$6.49M
ESPR
99
DELISTED
Esperion Therapeutics
ESPR
$22.6M 0.23%
4,519,164
– –
RMD icon
100
ResMed
RMD
$28.9B
$22.5M 0.23%
86,490
-1,655
-2% -$429K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2021 Portfolio in Review

As of Q4 2021, Bellevue Group held 234 positions worth $9.7B, down 1.5% from $9.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group deployed $293M of net new capital in Q4 2021, opening 14 new positions and adding to 60 existing holdings. Its largest new stake was AstraZeneca: 29,500 shares worth $3.44M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Baxter International, an estimated $38.1M trimmed.

  • Bellevue Group's largest Q4 2021 buy was AstraZeneca: 29,500 shares worth $3.44M.
  • Bellevue Group added most to CareDx in Q4 2021, an estimated $74.9M increase.
  • Bellevue Group's biggest Q4 2021 reduction was Baxter International, cutting an estimated $38.1M.
  • Bellevue Group fully exited HILL-ROM HOLDINGS, INC. in Q4 2021, selling an estimated $63.1M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.7B portfolio in Q4 2021.
  • Bellevue Group opened 14 new positions and closed 43 in Q4 2021.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $9.7B.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.